Drug major Lupin posted consolidated net profit of Rs.547 crore for the quarter ended March 31, 2015 compared to Rs.553 crore posted during the corresponding quarter a year back.
In a filing in the Bombay Stock Exchange, the company said the consolidated net profit dropped one percent during the fourth quarter of 2014-15.
It attributed the fall in profit to higher price erosion in the US as well as a slowdown in product approvals impacted growth in the quarter.
The total income of the company for the period under review has decreased from Rs.3,125.73 crore for the quarter ended March 31, 2014 to Rs.3,095.35 crore for the quarter ended March 31, 2015.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app